Robert A. Blake

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

Tumor Xenografts, Mouse Xenograft Models, Active Dose +18

SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling

Robert A. Blake, Martin A. Broome, Xiangdong Liu et al. · Molecular and Cellular Biology · 2000 · 583 citations · Full text

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

James G. Christensen, Randall Schreck, Jon Burrows et al. · PubMed · 2003 · 497 citations

Cancer Biology, Tumor Biology, C-met Kinase +20

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Alexander Laird, Peter Vajkoczy, Laura K. Shawver et al. · PubMed · 2000 · 497 citations

Pathology, Cancer Biology, Tumor Biology +23

USP7 small-molecule inhibitors interfere with ubiquitin binding

Lorna Kategaya, Paola Di Lello, Lionel Rougé et al. · Nature · 2017 · 332 citations · Full text

Molecular Docking, Ubiquitin Binding, Drug Target +7